Patent ID: 8735599
Filing Date: 2014-05-27
Classification: A61P,C07D

Abstract:
1. A compound of formula I: wherein: R R R A is a substituted aryl or heteroaryl group selected from 5-methyl-2H-imidazol-4yl, 2-aminothiazol-4-yl, 4-t-butylphenyl, 2-chlorophenyl, 2-chloro-6-methylpyrid-4-yl, 3-chlorophenyl, 4-chlorophenyl, 6-chloropyridin-3-yl, 3,4-dichlorophenyl, 2,4-difluorophenyl, 1,5-dimethyl-1H-pyrazol-3-yl, 2,4-dimethylthiazol-5-yl, 1-ethyl-3-methyl-1H-pyrazol-5-yl, 2-methoxyphenyl, 4-methoxyphenyl, 4-methylisoxazol-3-yl, 5-methylisoxazol-4-yl, 4-methylphenyl, 1-methyl-3-trifluoromethyl-1H-pyrazol-4-yl, 1-methyl-5-chloro-1H-pyrazol-4-yl, 5-methyl-1H-pyrazol-3-yl, 6-methylpyridin-3-yl, 2-pyrrolidin-3-ylphenyl, 4-(trifluoromethyl)phenyl, 6-(trifluoromethyl)pyridin-3-yl, 2,5-dimethyloxazol-4-yl, 2-aminothiazol-4-yl, 4-methylpyrazol-5-yl, 3-trifluoromethylpyrazol-4-yl, 2-methyl-3-trifluoromethylpyrazol-5-yl, 4-chloro-1,3-dimethylpyrazolo[3,4]pyridine, and 1-methylbenzimidazol-2-yl; R 4 is -[alkylene] p -nitrogen-containing heterocyclic, -[alkylene] p -nitrogen-containing substituted heterocyclic, -[alkylene] p -nitrogen-containing heteroaryl, -[alkylene] p -nitrogen-containing substituted heteroaryl, or -[alkylene] p —NR 10 R 11 wherein p is 1, selected from the group consisting of —(CH 2 ) 2 —NH 2 , —CH 2 -azetidin-3-yl, —CH 2 -(2,5-dihydropyrrol-3-yl), —(CH 2 ) 3 -imidazol-1-yl, —CH 2 -(1H-imidazol-4-yl), —CH 2 -pyridin-3-yl, —CH 2 -(2-hydroxypyridin-4-yl), —CH 2 -(6-hydroxypyridin-3-yl), —CH 2 -morpholin-2-yl, —CH 2 -pyrrolidin-3-yl, —CH 2 -(3-fluoropyrrolidin-3-yl), —CH 2 -(3-hydroxypyrrolidin-3-yl), —CH 2 -(4-fluoropyrrolidin-3-yl), —CH 2 -(4-hydroxypyrrolidin-3-yl), —CH 2 -(2-hydroxymethylpyrrolidin-3-yl), —CH 2 -piperidin-3-yl, —CH 2 -[1H-(1,2,3-triazol-4-yl)], —CH 2 CH(NH 2 )CH 2 OH, —(CH 2 ) 3 —NH 2 , —(CH 2 ) 3 —NHCH 3 , —(CH 2 ) 3 —N(CH 3 ) 2 , —(CH 2 ) 3 NH-(5-cyanopyridin-2-yl), —(CH 2 ) 3 NH-cyclopropyl, —(CH 2 ) 3 NH-cyclobutyl, —(CH 2 ) 3 -(1H-imidazol-2-yl), —(CH 2 ) 3 -(2-hydroxyethylpiperidin-1-yl), —(CH 2 ) 3 NHCH 2 -cyclopropyl, —CH 2 CHOHCH 2 NH 2 , —CH 2 CH(CH 2 OH)CH 2 NH 2 , —CH 2 C(CH 3 ) 2 CH 2 —N(CH 3 ) 2 , —CH 2 C(CH 3 ) 2 CH 2 -(4-methylpiperazin-1-yl), —(CH 2 ) 2 C(O)NH 2 , —(CH 2 ) 2 CH(NH 2 )C(O)NH 2 , —(CH 2 ) 2 CH(NH 2 )CH 2 OH, —(CH 2 ) 2 CH(NH 2 )CH 3 , —CH 2 CHFCH 2 NH 2 , —(CH 2 ) 3 —NHCH 2 CH 2 OH, —(CH 2 ) 3 —N(CH 2 CH 2 OH) 2 , —(CH 2 ) 3 —NHCH(CH 2 OH) 2 , —(CH 2 ) 3 CH 3 , —(CH 2 ) 2 CH(NH 2 )CH 2 OH, —(CH 2 ) 2 C(CH 3 ) 2 NH 2 , —(CH 2 ) 2 CH(NH 2 )CH 2 OCH 3 , —(CH 2 ) 2 CH(NH 2 )CH 2 F, and —CH 2 CHFCH(NH 2 )CH 2 OH; R wherein L is methylene and A and R